Table 3 Results of causal analysis of pulmonary embolism (exposure) and human blood metabolites (outcome)

pulmonary embolism

1-stearoylglycerophosphoethanolamine

MR Egger

− 0.01012

2.555

(− 5.0179,4.9977)

0.9971

Weighted median

−0.02833

0.9651

(−1.9199,1.8633)

0.9766

Inverse variance weighted

0.2539

0.8356

(−1.4192,1.8917)

0.7612

pulmonary embolism

X-12100--hydroxytryptophan

MR Egger

−1.129

1.59

(−4.2454,1.9874)

0.5288

Weighted median

−0.3097

0.6186

(−1.5222,0.9028)

0.6166

Inverse variance weighted

0.08013

0.5019

(−0.9036,1.0639)

0.8732

pulmonary embolism

X-12029

MR Egger

−1.365

1.078

(−3.4779,0.7479)

0.2946

Weighted median

0.007778

0.4192

(−0.8139,0.8294)

0.9852

Inverse variance weighted

0.3129

0.4308

(−0.5315,1.1573)

0.4675

pulmonary embolism

X-11412 subunit beta-2

MR Egger

−1.613

1.609

(−4.7666,1.5406)

0.3899

Weighted median

−0.456

0.6179

(−1.6671,0.7551)

0.4605

Inverse variance weighted

−0.1042

0.5212

(−1.1258,0.9174)

0.8415

pulmonary embolism

N1-methyladenosine

MR Egger

0.1411

0.9921

(−1.8034,2.0856)

0.8959

Weighted median

−0.3065

0.3746

(−1.0407,0.4277)

0.4133

Inverse variance weighted

−0.3298

0.3075

(−0.9325,0.2729)

0.2835

pulmonary embolism

valine

MR Egger

−0.2964

1.072

(−2.3975,1.8047)

0.8002

Weighted median

0.4962

0.3983

(−0.2844,1.2769)

0.2129

Inverse variance weighted

0.5772

0.3468

(−0.1025,1.2569)

0.09607